The United States continues to play a pivotal role in the global Adalimumab market due to its high prevalence of autoimmune disorders, advanced healthcare infrastructure, and increasing adoption of biologic therapies. Conditions such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ulcerative colitis affect millions of patients across the country, driving substantial demand for...